MCID: BRN056
MIFTS: 61

Bronchopulmonary Dysplasia

Categories: Rare diseases, Respiratory diseases, Fetal diseases

Aliases & Classifications for Bronchopulmonary Dysplasia

MalaCards integrated aliases for Bronchopulmonary Dysplasia:

Name: Bronchopulmonary Dysplasia 37 72 49 55 51 69 59
Bpd 49 55

Characteristics:

Orphanet epidemiological data:

55
bronchopulmonary dysplasia
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Infancy,Neonatal; Age of death: normal life expectancy;

Classifications:



External Ids:

Orphanet 55 ORPHA70589
MESH via Orphanet 42 D001997
UMLS via Orphanet 70 C0006287
ICD10 via Orphanet 33 P27.1
UMLS 69 C0006287

Summaries for Bronchopulmonary Dysplasia

NIH Rare Diseases : 49 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 70589Disease definitionBronchopulmonary dysplasia is a chronic respiratory disease that results from complications related to lung injury during the treatment of infant acute respiratory distress syndrome (see these terms) in low-birth-weight premature infants or from abnormal lung development in older infants. Clinical signs are tachypnea, tachycardia and signs of respiratory distress such as intercostal recession, grunting and nasal flaring.Visit the Orphanet disease page for more resources. Last updated: 2/29/2012

MalaCards based summary : Bronchopulmonary Dysplasia, also known as bpd, is related to bronchial disease and chorioamnionitis, and has symptoms including small for gestational age, premature birth and emphysema. An important gene associated with Bronchopulmonary Dysplasia is SCGB1A1 (Secretoglobin Family 1A Member 1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Interleukin-4 and 13 signaling. The drugs RespiGam and Procaterol have been mentioned in the context of this disorder. Affiliated tissues include Lung and Lung, and related phenotypes are homeostasis/metabolism and hematopoietic system

PubMed Health : 59
About bronchopulmonary dysplasia: Bronchopulmonary (BRONG-ko-PUL-mo-NAR-e) dysplasia (dis-PLA-ze-ah), or BPD, is a serious lung condition that affects infants. BPD mostly affects premature infants who need oxygen therapy (oxygen given through nasal prongs, a mask, or a breathing tube).Most infants who develop BPD are born more than 10 weeks before their due dates, weigh less than 2 pounds (about 1,000 grams) at birth, and have breathing problems. Infections that occur before or shortly after birth also can contribute to BPD.Some infants who have BPD may need long-term breathing support from nasal continuous positive airway pressure (NCPAP) machines or ventilators.

Wikipedia : 72 Bronchopulmonary dysplasia (BPD; formerly chronic lung disease of infancy) is a chronic lung disease in... more...

Related Diseases for Bronchopulmonary Dysplasia

Diseases related to Bronchopulmonary Dysplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Related Disease Score Top Affiliating Genes
1 bronchial disease 31.3 CXCL8 ELANE RNASE3
2 chorioamnionitis 30.6 CXCL8 ELANE FLT1
3 lung disease 30.6 CXCL8 ELANE SFTPB
4 respiratory failure 30.0 CXCL8 ELANE SCGB1A1 SFTPB
5 interstitial emphysema 29.9 ELANE FLT1
6 newborn respiratory distress syndrome 29.8 CXCL8 ELANE SCGB1A1 SFTPB
7 pulmonary disease, chronic obstructive 29.6 CXCL8 ELANE RNASE3
8 pneumonia 29.5 CXCL8 ELANE SCGB1A1 SFTPB
9 pulmonary fibrosis, idiopathic 28.6 CXCL8 ELANE IL1RN SCGB1A1 SFTPB TIMP1
10 asthma 27.8 CXCL8 ELANE IL1RN ITGAM RNASE3 SCGB1A1
11 borderline personality disorder 11.4
12 pulmonary hypertension, neonatal 11.0
13 pulmonary hypertension 10.5
14 toxicodendron dermatitis 10.5 CXCL8 SELL
15 felty syndrome 10.4 CXCL8 ELANE
16 paraquat lung 10.4 SCGB1A1 SFTPB
17 pouchitis 10.4 CXCL8 IL1RN
18 cardiac rupture 10.4 CXCL8 ELANE
19 cyclic neutropenia 10.4 CXCL8 ELANE
20 toxic pneumonitis 10.4 SCGB1A1 SFTPB
21 aging 10.4
22 capillary leak syndrome 10.4 CXCL8 ELANE
23 cryptogenic organizing pneumonia 10.3 CXCL8 TIMP1
24 necrotizing fasciitis 10.3 CXCL8 IL1RN
25 endotheliitis 10.3
26 arthus reaction 10.3 ELANE SELL
27 mid-dermal elastolysis 10.3 ELANE TIMP1
28 acute respiratory distress syndrome 10.3 CXCL8 ELANE SFTPB
29 aseptic meningitis 10.3 CXCL8 IL1RN
30 meconium aspiration syndrome 10.2 CXCL8 SCGB1A1 SFTPB
31 mild pre-eclampsia 10.2 FLT1 SOD1
32 lung giant cell carcinoma 10.2 CXCL8 TIMP1
33 personality disorder 10.2
34 cohen syndrome 10.2 ITGAM SELL
35 pneumoconiosis 10.2 CXCL8 SCGB1A1 SOD1
36 interstitial lung disease 10.2 CXCL8 SFTPB TIMP1
37 granulocytopenia 10.1 ITGAM SELL
38 acute hemorrhagic leukoencephalitis 10.1 FLT1 IL1RN
39 behcet syndrome 10.1 CXCL8 IL1RN SELL
40 pleural tuberculosis 10.1 CXCL8 TIMP1
41 silicosis 10.1 CXCL8 IL1RN SCGB1A1
42 pulmonary hypertension, primary, 1 10.1
43 oral candidiasis 10.1 CXCL8 IL1RN
44 periodontitis 10.1 CXCL8 ELANE TIMP1
45 shwartzman phenomenon 10.1 ITGAM SELL
46 patent ductus arteriosus 1 10.1
47 bone inflammation disease 10.1 CXCL8 IL1RN TIMP1
48 microcystic meningioma 10.1 FLT1 TIMP1
49 bronchiolitis obliterans 10.1 CXCL8 SCGB1A1 TIMP1
50 leukocyte adhesion deficiency, type i 10.1 ITGAM SELL

Graphical network of the top 20 diseases related to Bronchopulmonary Dysplasia:



Diseases related to Bronchopulmonary Dysplasia

Symptoms & Phenotypes for Bronchopulmonary Dysplasia

Human phenotypes related to Bronchopulmonary Dysplasia:

55 31 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 small for gestational age 55 31 hallmark (90%) Very frequent (99-80%) HP:0001518
2 premature birth 55 31 hallmark (90%) Very frequent (99-80%) HP:0001622
3 emphysema 55 31 hallmark (90%) Very frequent (99-80%) HP:0002097
4 respiratory distress 55 31 hallmark (90%) Very frequent (99-80%) HP:0002098
5 respiratory failure requiring assisted ventilation 55 31 hallmark (90%) Very frequent (99-80%) HP:0004887
6 chronic lung disease 55 31 hallmark (90%) Very frequent (99-80%) HP:0006528
7 hyperoxemia 55 31 hallmark (90%) Very frequent (99-80%) HP:0012419
8 cough 55 31 hallmark (90%) Very frequent (99-80%) HP:0012735
9 right ventricular hypertrophy 55 31 frequent (33%) Frequent (79-30%) HP:0001667
10 right ventricular failure 55 31 frequent (33%) Frequent (79-30%) HP:0001708
11 sleep disturbance 55 31 frequent (33%) Frequent (79-30%) HP:0002360
12 central apnea 55 31 frequent (33%) Frequent (79-30%) HP:0002871
13 exercise intolerance 55 31 frequent (33%) Frequent (79-30%) HP:0003546
14 diaphragmatic paralysis 55 31 frequent (33%) Frequent (79-30%) HP:0006597
15 wheezing 55 31 frequent (33%) Frequent (79-30%) HP:0030828
16 tracheobronchomalacia 55 31 occasional (7.5%) Occasional (29-5%) HP:0002786
17 pulmonary sequestration 55 31 occasional (7.5%) Occasional (29-5%) HP:0100632
18 atelectasis 55 31 occasional (7.5%) Occasional (29-5%) HP:0100750
19 abnormality of lung morphology 55 Very frequent (99-80%)
20 dyspnea 55 Very frequent (99-80%)
21 functional respiratory abnormality 55 Frequent (79-30%)
22 abnormal respiratory system morphology 55 Frequent (79-30%)

MGI Mouse Phenotypes related to Bronchopulmonary Dysplasia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.9 SOD1 ELANE TIMP1 FGF10 FLT1 IL1RN
2 hematopoietic system MP:0005397 9.86 SOD1 ELANE TIMP1 FGF10 FLT1 IL1RN
3 immune system MP:0005387 9.61 SOD1 ELANE TIMP1 FGF10 FLT1 IL1RN
4 neoplasm MP:0002006 9.02 SOD1 ELANE TIMP1 SCGB1A1 SELL

Drugs & Therapeutics for Bronchopulmonary Dysplasia

PubMedHealth treatment related to Bronchopulmonary Dysplasia: 59

If your doctor thinks you're going to give birth too early, he or she may give you injections of a corticosteroid medicine.The medicine can speed up surfactant production in your baby. Surfactant is a liquid that coats the inside of the lungs. It helps keep the lungs open so your infant can breathe in air once he or she is born.Corticosteroids also can help your baby's lungs, brain, and kidneys develop more quickly while he or she is in the womb.Premature babies who have very low birth weights also might be given corticosteroids within the first few days of birth. Doctors sometimes prescribe inhaled nitric oxide shortly after birth for babies who have very low birth weights. This treatment can help improve the babies' lung function.These preventive measures may help reduce infants' risk of respiratory distress syndrome (RDS), which can lead to BPD.

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
RespiGam 17 MedImmune January 1996

Drugs for Bronchopulmonary Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 220)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
2 Beractant Approved Phase 4,Phase 2,Phase 3 108778-82-1
3
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1 51333-22-3 5281004 63006
4 Poractant alfa Approved Phase 4,Phase 2,Phase 3 129069-19-8
5
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2 57-83-0 5994
6
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
7
Remifentanil Approved Phase 4,Phase 1,Phase 2 132875-61-7 60815
8
Caffeine Approved, Nutraceutical Phase 4,Phase 3 58-08-2 2519
9
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 77-92-9 311
10 Adrenergic Agents Phase 4
11 Adrenergic Agonists Phase 4
12 Adrenergic beta-2 Receptor Agonists Phase 4
13 Adrenergic beta-Agonists Phase 4
14 Albuterol Phase 4
15 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Tocolytic Agents Phase 4,Phase 3,Phase 2
22 Pulmonary Surfactants Phase 4,Phase 3,Phase 2,Phase 1
23 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
24 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
25 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
28 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Lactoferrin Phase 4
30 Antibodies Phase 4,Phase 3
31 Immunoglobulins Phase 4,Phase 3
32 Vaccines Phase 4
33 11-hydroxyprogesterone Phase 4,Phase 2,Phase 3
34 17-alpha-hydroxy-progesterone caproate Phase 4,Phase 2,Phase 3
35 Estrogen Antagonists Phase 4,Phase 2,Phase 3
36 Estrogens Phase 4,Phase 2,Phase 3
37 Progestins Phase 4,Phase 3,Phase 2
38 Anticoagulants Phase 4,Phase 3
39 Caffeine citrate Phase 4,Phase 3
40 Central Nervous System Stimulants Phase 4,Phase 3
41 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2
42 Purinergic P1 Receptor Antagonists Phase 4,Phase 3
43 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
44 Calcium, Dietary Phase 4
45 Chelating Agents Phase 4
46 Analgesics, Opioid Phase 4,Phase 1,Phase 2
47 Anesthetics Phase 4,Phase 3,Phase 1,Phase 2
48 Anesthetics, General Phase 4,Phase 1,Phase 2
49 Anesthetics, Intravenous Phase 4,Phase 1,Phase 2
50 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 299)

# Name Status NCT ID Phase Drugs
1 Preterm Infant Inhaled Albuterol Dosing Unknown status NCT02447250 Phase 4 Varied albuterol dose response
2 Surfactant Administration During Spontaneous Breathing Unknown status NCT01329432 Phase 4
3 Prevention of Chronic Lung Disease (CLD) in Preterm Infants Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
4 Early CPAP in Respiratory Distress Syndrome Unknown status NCT00368680 Phase 4
5 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia Completed NCT00926276 Phase 4
6 Early Versus Late Lactoferrin in Prevention of Neonatal Sepsis Completed NCT02959229 Phase 4 Lactoferrin;Placebo (for Lactoferrin)
7 Prevention of RSV Infections in Bone Marrow Transplant Recipients Completed NCT00001903 Phase 4 RSV Polyclonal Immunoglobulin
8 Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery Completed NCT00331695 Phase 4 17 alpha-hydroxyprogesterones caproate
9 Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part IV Completed NCT01604447 Phase 4
10 Evaluate the Use of Plastic Bags in Preventing and Treating Hypothermia in Neonates Completed NCT01403623 Phase 4
11 OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP Recruiting NCT02140580 Phase 4
12 Early Caffeine in Preterm Neonates Recruiting NCT03086473 Phase 4 Caffeine Citrate;Placebo (Normal Saline)
13 Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome Recruiting NCT02164734 Phase 4 remifentanil
14 Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia Active, not recruiting NCT01039285 Phase 4 Curosurf
15 Rate of Bronchopulmonary Dysplasia in Preterms Neonates: a Trial Comparing SMOFlipid and Medialipide Not yet recruiting NCT02853253 Phase 4
16 Intratracheal Budesonide/Surfactant Prevents BPD Not yet recruiting NCT03275415 Phase 4 budesonide;Saline
17 Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Terminated NCT00767039 Phase 4 Survanta (beractant);Curosurf (poractant)
18 Clarithromycin Prophylaxis in Preterm Infants Colonisation With Ureaplasma Urealyticum and Mycoplasma Hominis Unknown status NCT01652118 Phase 3 clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia;Saline
19 Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia Unknown status NCT01022580 Phase 3 Infasurf surfactant (ONY, Inc.)
20 Cysteine Supplementation in Critically Ill Neonates Unknown status NCT00254176 Phase 2, Phase 3
21 Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia Completed NCT01035190 Phase 3 Budesonide
22 Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Completed NCT00931632 Phase 3 Inhaled Nitric Oxide;Placebo
23 PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates Completed NCT00623740 Phase 3 hydrocortisone;placebo
24 Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia Completed NCT01503801 Phase 2, Phase 3 Nitric Oxide
25 Phase III Randomized, Double-Blind Study of Dexamethasone Vs Dexamethasone/Methylprednisolone Vs Placebo for Bronchopulmonary Dysplasia Completed NCT00004785 Phase 3 dexamethasone;methylprednisolone
26 Nasal Intermittent Positive Pressure Ventilation in Premature Infants (NIPPV) Completed NCT00433212 Phase 3
27 Inhaled Beclomethasone to Prevent Chronic Lung Disease Completed NCT00000576 Phase 3 beclomethasone
28 Post-hospitalization Nursing Effectiveness (PHONE) Study Completed NCT00314431 Phase 3
29 Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome Completed NCT01203358 Phase 2, Phase 3 Exosurf;Survanta
30 Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide Completed NCT00569530 Phase 3 Infasurf (ONY Inc.);Sham
31 Inhaled NO in Prevention of Chronic Lung Disease Completed NCT00000548 Phase 3
32 Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants Completed NCT00006401 Phase 3 iNO
33 Randomized Trial of Nasal Continuous Positive Airway Pressure or Synchronized Nasal Ventilation in Premature Infants. Completed NCT00188968 Phase 3
34 Surfactant Positive Airway Pressure and Pulse Oximetry Trial Completed NCT00233324 Phase 3 Surfactant;Supplemental oxygen with target saturation of 85 to 89%;Supplemental oxygen with target saturation of 91 to 95%
35 Vitamin D Supplementation for Extremely Preterm Infants Completed NCT01600430 Phase 2, Phase 3
36 High Frequency Ventilation in Premature Infants (HIFI) Completed NCT00000567 Phase 3
37 Premature Infants in Need of Transfusion (PINT) Completed NCT00182390 Phase 3
38 Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children Completed NCT01006629 Phase 2, Phase 3
39 The Effect of Sildenafil in Preterm Infants With Evolving Chronic Lung Disease Completed NCT00431418 Phase 3 Sildenafil;Placebo
40 Dexamethasone Therapy in VLBW Infants at Risk of CLD Completed NCT00011362 Phase 3 Dexamethasone Early;Dexamethasone Late
41 Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies Completed NCT00551642 Phase 3 Nitric Oxide for inhalation;Nitrogen
42 A Multicenter, Randomized, Open Label Trial of a New Animal Extracted Surfactant to Treat RDS in Preterm Infants Completed NCT02305160 Phase 2, Phase 3 Butantan;Control
43 Prolonged Outcomes After Nitric Oxide (PrONOx) Completed NCT00234247 Phase 3
44 Safety Study of Home Oxygen Therapy for Children With Acute Bronchiolitis Completed NCT00677066 Phase 3
45 Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis Completed NCT02954926 Phase 3 IVIG
46 PREGNANT Short Cervix Trial Completed NCT00615550 Phase 3 progesterone;placebo
47 A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus Completed NCT02968173 Phase 3 Palivizumab
48 Oxygen Toxicity in the Resuscitation in Extremely Premature Infants Completed NCT00494702 Phase 3
49 Caffeine for Apnea of Prematurity (CAP) Completed NCT00182312 Phase 3 Caffeine citrate injection
50 NIV Strategies for RDS in Preterm Infants. NIV (Non Invasive Ventilation), RDS (Respiratory Distress Syndrome) Completed NCT02259400 Phase 2, Phase 3

Search NIH Clinical Center for Bronchopulmonary Dysplasia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bronchopulmonary Dysplasia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bronchopulmonary Dysplasia:
PNEUMOSTEM

Genetic Tests for Bronchopulmonary Dysplasia

Anatomical Context for Bronchopulmonary Dysplasia

MalaCards organs/tissues related to Bronchopulmonary Dysplasia:

38
Lung, Brain, Endothelial, Cervix, Bone, Heart, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Bronchopulmonary Dysplasia:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Alveoli Alveolar Epithelial Type 1 Cells Potential therapeutic candidate, affected by disease
2 Lung Alveoli Alveolar Epithelial Type 2 Cells Potential therapeutic candidate, affected by disease
3 Lung Pulmonary Capillary Plexus Affected by disease

Publications for Bronchopulmonary Dysplasia

Articles related to Bronchopulmonary Dysplasia:

(show top 50) (show all 753)
# Title Authors Year
1
Brainstem auditory abnormality in extremely premature babies and the impact of neonatal bronchopulmonary dysplasia. ( 29381192 )
2018
2
Recent Advances in Bronchopulmonary Dysplasia: Pathophysiology, Prevention, and Treatment. ( 29374791 )
2018
3
Decreased ZONAB expression promotes excessive transdifferentiation of alveolar epithelial cells in hyperoxia-induced bronchopulmonary dysplasia. ( 29393348 )
2018
4
Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia. ( 29320647 )
2018
5
Anti-VEGF Antagonists, a Potential Primary Prevention for Bronchopulmonary Dysplasia? ( 29298393 )
2018
6
Why do children with severe Bronchopulmonary Dysplasia not attend neonatal follow-up care? Parental views of barriers. ( 29420848 )
2018
7
The changing relationship between bronchopulmonary dysplasia and cognition in very preterm infants. ( 29333635 )
2018
8
Morphological characterization of pulmonary microvascular disease in bronchopulmonary dysplasia caused by hyperoxia in newborn mice. ( 29362947 )
2018
9
Aurothioglucose Does Not Improve Alveolarization or Elicit Sustained Nrf2 Activation in C57Bl/6 Models of Bronchopulmonary Dysplasia. ( 29368550 )
2018
10
Role of vitamin A supplementation in prevention of Bronchopulmonary dysplasia in extremely low birth weight neonates: A systematic review of randomized trials. ( 29447482 )
2018
11
Aerosolized deferoxamine administration in mouse model of bronchopulmonary dysplasia improve pulmonary development. ( 29423017 )
2018
12
Upregulation of Vascular Endothelial Growth Factor in Amniotic Fluid Stem Cells Enhances Their Potential to Attenuate Lung Injury in a Preterm Rabbit Model of Bronchopulmonary Dysplasia. ( 29393249 )
2018
13
A Shared Pattern of I^-Catenin Activation in Bronchopulmonary Dysplasia and Idiopathic Pulmonary Fibrosis. ( 29355514 )
2018
14
Prevention of bronchopulmonary dysplasia in extremely low gestational age neonates: current evidence. ( 29363502 )
2018
15
Ceramides in tracheal aspirates of preterm infants: Marker for bronchopulmonary dysplasia. ( 29346372 )
2018
16
Respiratory Phenotypes for Preterm Infants, Children, and Adults: Bronchopulmonary Dysplasia and More. ( 29328889 )
2018
17
Quercetin attenuates the hyperoxic lung injury in neonatal mice: Implications for Bronchopulmonary dysplasia (BPD). ( 29432836 )
2018
18
Volume targeting levels and work of breathing in infants with evolving or established bronchopulmonary dysplasia. ( 29305407 )
2018
19
Chorioamnionitis: Is a major player in the development of bronchopulmonary dysplasia? ( 28861110 )
2017
20
Tracheobronchomalacia Is Associated with Increased Morbidity in Bronchopulmonary Dysplasia. ( 28622012 )
2017
21
Impact of Diuretic Therapy in the Treatment of Bronchopulmonary Dysplasia and Acute Kidney Injury in the Neonatal Population. ( 28857765 )
2017
22
Late (a8Y 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. ( 28836266 )
2017
23
Can We Prevent Bronchopulmonary Dysplasia? ( 28947055 )
2017
24
Respiratory outcomes after initial hospital discharge in children with ventricular shunts and bronchopulmonary dysplasia. ( 28941226 )
2017
25
Clinical Utility of Echocardiography for Early and Late Pulmonary Hypertension in Preterm Infants: Relation with Bronchopulmonary Dysplasia. ( 29333219 )
2017
26
Trends of urinary beta-2-microglobulin levels and bronchopulmonary dysplasia in preterm infants. ( 28833913 )
2017
27
Deep Illumina sequencing reveals differential expression of long non-coding RNAs in hyperoxia induced bronchopulmonary dysplasia in a rat model. ( 29312522 )
2017
28
Pulmonary vein stenosis of ex-premature infants with pulmonary hypertension and bronchopulmonary dysplasia, epidemiology, and survival from a multicenter cohort. ( 28152279 )
2017
29
GSTP1 and CYP2B6 Genetic Polymorphisms and the Risk of Bronchopulmonary Dysplasia in Preterm Neonates. ( 28081574 )
2017
30
Histologic Chorioamnionitis and Bronchopulmonary Dysplasia in Preterm Infants: The Epidemiologic Study on Low Gestational Ages 2 Cohort. ( 28583707 )
2017
31
Bronchopulmonary dysplasia-associated pulmonary hypertension: clues from placental pathology. ( 28880261 )
2017
32
Medical Progress Series: Bronchopulmonary Dysplasia at 50 Years-An Introduction. ( 28843303 )
2017
33
Modelling bronchopulmonary dysplasia in animals: arguments for the preterm rabbit model. ( 28950821 )
2017
34
Can We Cure Bronchopulmonary Dysplasia? ( 28942897 )
2017
35
Therapeutic effects of fibroblast growth factor-10 on hyperoxia-induced bronchopulmonary dysplasia in neonatal mice. ( 28861146 )
2017
36
Genome-wide association study of bronchopulmonary dysplasia: a potential role for variants near the CRP gene. ( 28839172 )
2017
37
Biomarkers associated with bronchopulmonary dysplasia/mortality in premature infants. ( 27893721 )
2017
38
Bronchopulmonary Dysplasia. ( 28855707 )
2017
39
Effects of the early administration of sivelestat sodium on bronchopulmonary dysplasia in infants: A retrospective cohort study. ( 28950234 )
2017
40
Expression profiling of genes regulated by sphingosine kinase1 signaling in a murine model of hyperoxia induced neonatal bronchopulmonary dysplasia. ( 28851267 )
2017
41
Mesenchymal stem cells in the pathogenesis and treatment of bronchopulmonary dysplasia: A clinical review. ( 28945702 )
2017
42
Bronchopulmonary dysplasia: incidence and risk factors. ( 28895695 )
2017
43
Bronchopulmonary dysplasia and pulmonary hypertension: a meta-analysis. ( 28079864 )
2017
44
Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function Through Macrophage Immunomodulation. ( 28853608 )
2017
45
The economic impact of prematurity and bronchopulmonary dysplasia. ( 28889192 )
2017
46
Bronchopulmonary Dysplasia: Chronic Lung Disease of Infancy and Long-Term Pulmonary Outcomes. ( 28067830 )
2017
47
Early Elevation of Plasma Periostin Is Associated with Chronic Ventilator-Dependent Bronchopulmonary Dysplasia. ( 27905846 )
2016
48
Antibiotic Exposure and Risk for Death or Bronchopulmonary Dysplasia in Very Low Birth Weight Infants. ( 27908652 )
2016
49
Pathophysiology, screening and diagnosis of pulmonary hypertension in infants with bronchopulmonary dysplasia - A review of the literature. ( 27986502 )
2016
50
Refining anti-inflammatory therapy strategies for bronchopulmonary dysplasia. ( 27957795 )
2016

Variations for Bronchopulmonary Dysplasia

Expression for Bronchopulmonary Dysplasia

Search GEO for disease gene expression data for Bronchopulmonary Dysplasia.

Pathways for Bronchopulmonary Dysplasia

Pathways related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.53 CXCL8 ELANE FLT1 ITGAM
2 11.49 CXCL8 ITGAM TIMP1
3 10.49 CXCL8 IL1RN TIMP1
4 10.46 CXCL8 FGF10 FLT1 ITGAM TIMP1

GO Terms for Bronchopulmonary Dysplasia

Cellular components related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.86 ELANE IL1RN ITGAM RBP4 RNASE3 SCGB1A1
2 extracellular region GO:0005576 9.7 CXCL8 ELANE FGF10 FLT1 IL1RN RBP4
3 extracellular space GO:0005615 9.4 CXCL8 ELANE FGF10 FLT1 IL1RN ITGAM
4 secretory granule GO:0030141 9.33 ELANE SCGB1A1 SOD1

Biological processes related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.76 ELANE ITGAM RNASE3 SELL
2 regulation of receptor activity GO:0010469 9.71 CXCL8 FGF10 IL1RN TIMP1
3 response to lipopolysaccharide GO:0032496 9.67 ELANE FGF10 SCGB1A1
4 chemotaxis GO:0006935 9.61 CXCL8 FGF10 FLT1
5 blood vessel morphogenesis GO:0048514 9.48 FGF10 FLT1
6 embryonic digestive tract development GO:0048566 9.37 CXCL8 FGF10
7 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.32 FGF10 FLT1
8 positive regulation of superoxide anion generation GO:0032930 9.26 ITGAM SOD1
9 induction of positive chemotaxis GO:0050930 9.16 CXCL8 FGF10
10 response to organic substance GO:0010033 9.13 SCGB1A1 SOD1 TIMP1
11 female genitalia morphogenesis GO:0048807 8.62 FGF10 RBP4

Molecular functions related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.13 ELANE FGF10 SELL
2 protease binding GO:0002020 8.8 ELANE SELL TIMP1

Sources for Bronchopulmonary Dysplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....